Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term colorectal cancer (CRC) incidence and ...

Results from a new JAMA Network study support the large-scale use of FIT tests. The findings show that those who complete one or more fecal immunochemical test (FIT) screenings are associated with a ...

Stool DNA testing climbed sharply after the pandemic began while colonoscopy and fecal immunochemical test use fell, a study of nearly 25 million privately insured Blue Cross Blue Shield beneficiaries ...

Colorectal cancer continues to be one of the leading causes of cancer-related deaths worldwide. However, recent advancements in medical screening have brought new hope in the fight against this deadly ...

VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...

Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...

Please provide your email address to receive an email when new articles are posted on . Annual fecal immunochemical testing was the most effective and cheapest CRC screening method for underserved ...

Targeted interventions by patient characteristics to improve fecal immunochemical test completion could reduce disparities in colorectal cancer screening and improve overall compliance with screening ...

Screening annually with a method like OC-Auto FIT improves outcomes and delivers greater cost-effectiveness. Key findings from the study include: Annual FIT-based screening produced fewer CRC cases, ...

Please provide your email address to receive an email when new articles are posted on . Multi-target stool DNA screening tests predicted neoplasia at follow-up colonoscopy more often than fecal ...

Colorectal cancer (CRC) is a leading cause of death among men and women in the USA. Encouragingly, the reported death rates from CRC in the USA have dropped by 46%, and screening has had an important ...